HEALTHglobal
Masked T‑cell engagers: Cancer immunotherapies for the future?
Single source
Updated 2 hours ago
First seen March 20, 2026 10:55:49Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own immune arsenal to fight cancer.